Journey Medical reports Q2 EPS (16c) vs. (17c) last year

Reports Q2 revenue $15.01M, consensus $14.8M. Claude Maraoui, Journey Medical’s (DERM) co-founder, president and CEO, said, “We are pleased to report solid results for the second quarter of 2025, with total revenue of $15 million and a net sales contribution from Emrosi of $2.8 million during the period. The second quarter marks the first full quarter since Emrosi entered the market, and in a short period of time, we have delivered a strong initial prescription ramp for the product while payer coverage continues to expand. This momentum reflects growing physician and payer adoption, and confidence in Emrosi’s differentiated profile, including statistically superior efficacy versus Oracea(R) and placebo, as published in the Journal of the American Medical Association – Dermatology. With the Emrosi launch showing strong traction out of the gate, continued improvement in cash generation, and the execution of our focused dermatology commercial organization, we believe Journey Medical is well-positioned for continued growth and operating leverage in the second half of 2025 and beyond.”